1. Home
  2. TYL vs NTRA Comparison

TYL vs NTRA Comparison

Compare TYL & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyler Technologies Inc.

TYL

Tyler Technologies Inc.

HOLD

Current Price

$468.39

Market Cap

20.2B

Sector

Technology

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$244.06

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYL
NTRA
Founded
1966
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.2B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
TYL
NTRA
Price
$468.39
$244.06
Analyst Decision
Buy
Strong Buy
Analyst Count
9
16
Target Price
$666.78
$227.69
AVG Volume (30 Days)
378.0K
1.7M
Earning Date
10-29-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
31.32
N/A
EPS
7.19
N/A
Revenue
$2,298,292,000.00
$2,116,676,000.00
Revenue This Year
$10.96
$32.77
Revenue Next Year
$8.90
$16.51
P/E Ratio
$65.26
N/A
Revenue Growth
10.62
38.17
52 Week Low
$450.00
$125.38
52 Week High
$661.31
$245.59

Technical Indicators

Market Signals
Indicator
TYL
NTRA
Relative Strength Index (RSI) 47.17 80.03
Support Level $460.60 $233.67
Resistance Level $469.29 $240.18
Average True Range (ATR) 9.94 7.39
MACD 2.01 0.68
Stochastic Oscillator 57.34 97.49

Price Performance

Historical Comparison
TYL
NTRA

About TYL Tyler Technologies Inc.

Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: